Viome, the Bellevue, Wash.-based wellness and diagnostics company, is putting its efforts around preventive healthcare and longevity where its mouth is. The company unveiled new toothpaste and gel products Wednesday as part of its Oral Health Solution system.
Targeting the large percentages of U.S. adults who have been affected by tooth decay and/or gum disease, Viome says “traditional toothpastes aren’t working.” The company says it created its personalized MyBiotics Toothpaste and Gel based on insights from its Oral Health Intelligence test, designed to help people discover the connection between their oral microbes and the health of their teeth, gums, and breath.
The oral microbiome harbors more than 700 species of bacteria and “is crucial in maintaining oral as well as systemic health,” according to a 2018 study.
Founded eight years ago by serial entrepreneur Naveen Jain, Viome set out to analyze the gut microbiome and its impact on overall systemic health. The company sells at-home kits that analyze the microbial composition of stool samples and provides food recommendations, as well as supplements and probiotics.
In the last few years, Viome has sought to understand the oral microbiome and create products designed to boost the mouth’s defense mechanisms naturally.
The MyBiotics Gel is designed for a deep morning clean, to remove plaque and repel bacteria. Viome says the gel is formulated from 26 research studies at top U.S. universities.
The MyBiotics Toothpaste is an oral supplement that includes each user’s personalized formula — including prebiotics, postbiotics and other ingredients — based on an Oral Health Score. The cost, which includes the oral health test and the gel and toothpaste, is $79 per month, with a three-month commitment required.
There are a number of startups taking on oral hygiene giants with their own toothpastes and other oral care products.
Viome says its insights are powered by marrying proprietary RNA sequencing methods with artificial intelligence.
The company raised an $86.5 million Series C round last August, and announced a deal with CVS to sell its gut microbiome test in 200 CVS locations across the U.S. Total funding is $175 million.
Viome has a majority of its workforce in the Seattle region, with a corporate office in Bellevue and a lab in Bothell.
https://ift.tt/nS5spGK July 17, 2024 at 01:00PM GeekWire
Post a Comment
0Comments